APA (7th ed.) Citation

ZC, F., XG, C., GW, Z., RG, S., LJ, Z., HT, S., & JX, H. (2024). Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China. International journal of rheumatic diseases, 27(5), e15190. https://doi.org/10.1111/1756-185X.15190

Chicago Style (17th ed.) Citation

ZC, Fu, Cheng XG, Zhang GW, Shi RG, Zhang LJ, Sun HT, and Huang JX. "Comparable Drug Levels and Immunogenicity in Patients with Axial Spondyloarthritis Treated with Adalimumab Originator and Biosimilar: A Retrospective Study from Two Centers of China." International Journal of Rheumatic Diseases 27, no. 5 (2024): e15190. https://doi.org/10.1111/1756-185X.15190.

MLA (9th ed.) Citation

ZC, Fu, et al. "Comparable Drug Levels and Immunogenicity in Patients with Axial Spondyloarthritis Treated with Adalimumab Originator and Biosimilar: A Retrospective Study from Two Centers of China." International Journal of Rheumatic Diseases, vol. 27, no. 5, 2024, p. e15190, https://doi.org/10.1111/1756-185X.15190.